Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NASDAQ:ITMR NYSE:PHR NASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$14.22+7.4%$10.79$6.36▼$37.08$2.02B1.12.33 million shs2.42 million shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/APHRPhreesia$28.09-10.0%$28.34$17.07▼$32.76$1.67B0.72819,069 shs2.67 million shsQDELQuidelOrtho$28.68+3.2%$27.06$22.05▼$49.45$1.95B0.141.11 million shs971,432 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics+7.40%+5.41%+22.69%-3.27%-57.88%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%PHRPhreesia-10.27%-11.29%+3.61%+4.91%+16.22%QDELQuidelOrtho+3.20%-0.03%+22.35%-2.88%-28.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$14.22+7.4%$10.79$6.36▼$37.08$2.02B1.12.33 million shs2.42 million shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/APHRPhreesia$28.09-10.0%$28.34$17.07▼$32.76$1.67B0.72819,069 shs2.67 million shsQDELQuidelOrtho$28.68+3.2%$27.06$22.05▼$49.45$1.95B0.141.11 million shs971,432 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics+7.40%+5.41%+22.69%-3.27%-57.88%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%PHRPhreesia-10.27%-11.29%+3.61%+4.91%+16.22%QDELQuidelOrtho+3.20%-0.03%+22.35%-2.88%-28.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 3.06Buy$34.07139.57% UpsideITMRItamar Medical 0.00N/AN/AN/APHRPhreesia 3.00Buy$33.3118.57% UpsideQDELQuidelOrtho 2.33Hold$39.2036.68% UpsideCurrent Analyst Ratings BreakdownLatest ITMR, QDEL, DYN, and PHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025PHRPhreesiaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$34.00 ➝ $38.009/5/2025PHRPhreesiaNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.009/5/2025PHRPhreesiaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $34.009/5/2025PHRPhreesiaDA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$33.009/3/2025PHRPhreesiaStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$32.008/27/2025PHRPhreesiaMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$36.008/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/7/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$29.00 ➝ $26.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$34.00 ➝ $13.008/6/2025QDELQuidelOrthoCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $36.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AITMRItamar Medical$41.03M12.12N/AN/AN/A∞PHRPhreesia$449.67M3.72N/AN/A$4.56 per share6.16QDELQuidelOrtho$2.78B0.70$35.41 per share0.81$44.38 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)ITMRItamar MedicalN/A-$1.35N/AN/AN/AN/AN/AN/AN/APHRPhreesia-$58.53M-$0.42N/AN/AN/A-5.35%-9.00%-6.20%N/AQDELQuidelOrtho-$2.05B-$6.54N/A8.93N/A-16.10%5.29%2.43%11/6/2025 (Estimated)Latest ITMR, QDEL, DYN, and PHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q2 2026PHRPhreesia-$0.07$0.01+$0.08$0.01$116.39 million$117.26 million8/5/2025Q2 2025QDELQuidelOrtho$0.0122$0.12+$0.1078-$3.77$612.36 million$613.90 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/AITMRItamar MedicalN/AN/AN/AN/AN/APHRPhreesiaN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1716.8316.83ITMRItamar MedicalN/AN/AN/APHRPhreesia0.021.951.95QDELQuidelOrtho0.741.120.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%ITMRItamar Medical42.19%PHRPhreesia92.10%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics14.14%ITMRItamar MedicalN/APHRPhreesia5.50%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100142.26 million122.15 millionOptionableITMRItamar Medical25716.11 millionN/ANot OptionablePHRPhreesia2,08259.50 million56.23 millionOptionableQDELQuidelOrtho6,60067.90 million67.36 millionOptionableITMR, QDEL, DYN, and PHR HeadlinesRecent News About These CompaniesQuidelOrtho Corporation $QDEL Shares Sold by Magnetar Financial LLCSeptember 5 at 4:35 AM | marketbeat.comQUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 4 at 5:35 PM | globenewswire.com67,619 Shares in QuidelOrtho Corporation $QDEL Purchased by Birchview Capital LPSeptember 4 at 7:16 AM | marketbeat.comHBK Investments L P Has $16.88 Million Stock Holdings in QuidelOrtho Corporation $QDELSeptember 3 at 8:13 AM | marketbeat.comQuidelOrtho Corporation $QDEL Holdings Increased by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.comIeq Capital LLC Increases Holdings in QuidelOrtho Corporation $QDELAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Has $1.42 Million Holdings in QuidelOrtho Corporation $QDELAugust 30, 2025 | marketbeat.comQuidelOrtho to Participate in the Baird 2025 Global Healthcare ConferenceAugust 28, 2025 | prnewswire.comJump Financial LLC Boosts Stake in QuidelOrtho Corporation $QDELAugust 28, 2025 | marketbeat.com221,658 Shares in QuidelOrtho Corporation $QDEL Acquired by Nuveen LLCAugust 27, 2025 | marketbeat.comQuidelOrtho Completes Major Debt Refinancing TransactionAugust 23, 2025 | theglobeandmail.comT. Rowe Price Investment Management Inc. Has $400.31 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 23, 2025 | marketbeat.comQuidelOrtho Corporation: QuidelOrtho Completes Debt RefinancingAugust 22, 2025 | finanznachrichten.deAmerican Century Companies Inc. Increases Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $28.99 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comQuidelOrtho Completes Debt Refinancing | QDEL Stock NewsAugust 21, 2025 | gurufocus.comQuidelOrtho Completes Debt RefinancingAugust 21, 2025 | prnewswire.comScience Bytes Podcast Explores How Diagnostics Can Help Protect Students and CommunitiesAugust 21, 2025 | prnewswire.comQuidelOrtho Corporation $QDEL Shares Sold by Van Lanschot Kempen Investment Management N.V.August 21, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Shares Sold by Vanguard Group Inc.August 20, 2025 | marketbeat.comQuidelOrtho Corp (QDEL) Appoints Erich Wolff as Executive Vice President | QDEL stock newsAugust 19, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITMR, QDEL, DYN, and PHR Company DescriptionsDyne Therapeutics NASDAQ:DYN$14.22 +0.98 (+7.40%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.76 -0.46 (-3.20%) As of 09/5/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Itamar Medical NASDAQ:ITMRItamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.Phreesia NYSE:PHR$28.09 -3.12 (-10.00%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$29.07 +0.98 (+3.49%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.QuidelOrtho NASDAQ:QDEL$28.68 +0.89 (+3.20%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$28.68 0.00 (0.00%) As of 09/5/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
